- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Global Parkinson's Disease Market to Drop by $0.5 Billion by 2019, Says Report
The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).
The global Parkinson’s Disease market will decline from $3.4 billion in 2012 to $2.9 billion by 2019 (a negative Compound Annual Growth Rate of 2.3%), according to a new report by GBI Research (New York, NY).
With PD drugs such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone) set to lose their patents by the end of the forecast period, even the approval and launch of late-stage pipeline drugs for PD, including Rytary, safinamide and pimavanserin, “won’t be significant enough to diminish the impact of generic erosion,” says GBI Research Analyst Angel Wong.
However, disease-modifying treatment for PD remains an urgent unmet need. But with 87% of neuroprotective treatments still in early-stage development, these medications face several challenges, not least “the need for a reliable biomarker that can accelerate such development,” adds Wong.
To access the GBI Research report, click here.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
